CSIMarket Company Name, Ticker, Customers, else..
 
Emergent Biosolutions Inc   (NYSE: EBS)
 
Price: $6.0000 $-0.21 -3.382%
Day's High: $6.09499979019165 Week Perf: -3.54 %
Day's Low: $ 5.96 30 Day Perf: 23.97 %
Volume (M): 702,796 52 Wk High: $ 14.06
Volume (M$): $ 0 52 Wk Avg: $9.10
Open: $6.15 52 Wk Low: $4.36



 Market Capitalization (Millions $) 310
 Shares Outstanding (Millions) 52
 Employees 900
 Revenues (TTM) (Millions $) 770
 Net Income (TTM) (Millions $) -177
 Cash Flow (TTM) (Millions $) -110
 Capital Exp. (TTM) (Millions $) 12

Business Description


Emergent BioSolutions Inc. is a publicly traded biotechnology company headquartered in Gaithersburg, Maryland, USA. The company specializes in the development, manufacturing, and commercialization of vaccines and immunotherapies for infectious diseases and biodefense.

Founded in 1998, Emergent BioSolutions has grown to become a leading provider of medical countermeasures to governments, militaries, and private organizations around the world. The company's portfolio of products includes vaccines for anthrax, smallpox, and typhoid fever, as well as treatments for botulism and nerve agents.

Emergent BioSolutions operates a state-of-the-art manufacturing facility in Baltimore, Maryland, which has the capacity to produce millions of vaccine doses per year. The facility is equipped with advanced technologies and processes to ensure the highest levels of quality and safety.

The company has a strong focus on research and development, with dedicated teams working on the discovery and development of new vaccines and therapies. Emergent BioSolutions also partners with leading academic and research institutions to accelerate the development of breakthrough treatments.

In addition to its biodefense work, Emergent BioSolutions is actively involved in developing treatments for infectious diseases such as COVID-19. The company has partnered with other biotech firms and government agencies to develop potential treatments and vaccines for the virus.

Overall, Emergent BioSolutions Inc. is a dynamic and innovative biotech company that is dedicated to improving public health and safety through the development and manufacturing of life-saving vaccines and therapies.


   Company Address: 300 Professional Drive Gaithersburg, 20879 MD
   Company Phone Number: 631-3200   Stock Exchange / Ticker: NYSE EBS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        1.23% 
MRK        0.47% 
OPK        8.16% 
PFE   -2.35%    
RCUS   -0.75%    
SIGA        1.91% 
• View Complete Report
   



Contract

In an era where the capacities for rapid response to biological threats have become paramount, Emergent Bio...

Published Fri, Sep 19 2025 4:51 PM UTC

Emergent BioSolutions Secures $29 Million in Medical Countermeasure Orders: A Strategic Boost Amid Global Health Preparedness In an era where the capacities for rapid response to biological threats have become paramount, Emergent BioSolutions Inc. (NYSE: EBS), a prominent player in the bio-pharmaceutical sector, has recently solidified its position within the global medical ...
Management Announcement

Emergent BioSolutions Navigates Financial Crossroads: Strategic Sale and Defense Contracts Amidst Market Volatility

Published Wed, Mar 19 2025 8:30 PM UTC

In a pivotal moment for Emergent BioSolutions Inc. (NYSE:EBS), the company has finalized the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a transaction valued at approximately $36.5 million. This sale, announced on March 19, 2025, marks a significant shift in Emergent’s operational strategy as it refocuses on its core compet...
Contract

Emergent BioSolutions Secures $20 Million Contract with the U.S. Department of Defense Amidst Market Challenges

Published Wed, Jan 8 2025 12:47 PM UTC

In a significant development for public health preparedness, Emergent BioSolutions Inc. recently announced the exercise of a contract option valued at approximately $20 million for the supply of BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). This contract modification underscores the federal government’s commitment to maintaining a robust stoc...
Contract

Strategic Developments in Biodefense Emergent BioSolutions Recent Contract Enhancements and Organizational Adjustments

Published Sun, Dec 29 2024 7:31 PM UTC

Emergent BioSolutions Inc. a leading player in the biopharmaceutical sector, is intensifying its focus on biodefense preparedness through recent contract modifications with the U.S. government and operational restructuring. This article examines the implications of a $50 million contract option awarded by the Biomedical Advanced Research and Development Authority (BARDA) ...
Clinical Study

Evaluating Brincidofovir for Mpox Virus A Critical Clinical Trial Amidst Competitive Market Challenges for Emergent ...

Published Wed, Nov 6 2024 9:49 PM UTC

In recent developments concerning infectious disease management, Emergent BioSolutions Inc. has announced its participation in a clinical trial evaluating the safety and efficacy of brincidofovir (brand name TEMBEXA) in treating the mpox virus across Africa. Sponsored by PANTHER and led by the Africa Centres for Disease Control and Prevention, this randomized, double-blind,...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.40
Price to Sales (Expected) -
Price to Book 0.91
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.14
Working Capital Ratio 5.59
Leverage Ratio (MRQ) 2.27
Total Debt to Equity 1.73
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.47 $
Revenues (TTM) 14.93 $
Cash Flow (TTM) -
Cash 2.71 $
Book Value 6.62 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 855,778
Net Income per Employee (TTM) -196,444
Receivable Turnover Ratio (TTM) 5.65
Inventory Turnover Ratio (TTM) 1.02
Asset Turnover Ratio (TTM) 0.56

Profitability Ratios Current
Gross Margin (MRQ) 58.56 %
Operating Margin (MRQ) -53.39 %
Net Margin (MRQ) -76.91 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Emergent Biosolutions Inc's Segments
Product and Service    160.69 % of total Revenue
Contracts and grants    5.93 % of total Revenue
Commercial Product    40.67 % of total Revenue
Medical Countermeasures (mcm) Product    115.15 % of total Revenue
All other revenue    10.8 % of total Revenue
Commercial Products    40.67 % of total Revenue
MCM Products    115.15 % of total Revenue
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment    10.8 % of total Revenue

  Emergent Biosolutions Inc Outlook

On April 22 2024 the Emergent Biosolutions Inc provided following guidance

On April 22, 2024, Emergent BioSolutions Inc. announced that they will be releasing their financial results for the first quarter of 2024 and conducting a conference call on May 1, 2024, at 5:00 pm Eastern Time. During the call, they will discuss key business updates, provide revenue guidance for the second quarter of 2024, and share their financial outlook for the full year 2024.

Investors and stakeholders are encouraged to participate in the conference call to gain insight into Emergent BioSolutions' performance and future plans. The company, listed as NYSE: EBS, is headquartered in Gaithersburg, Maryland, and is a leader in providing biopharmaceutical products for various health challenges.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.